HSP90AB1 and cancer: Furthermore, even if resistance to targeted therapeutic agents has already developed, it has been reported that the vulnerability of resistant cancer cells can be exploited and therapeutic responses can be restored; this is by further combining agents with novel mechanisms of action, such as HSP90 inhibitors [48].